These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Search MEDLINE/PubMed


  • Title: Studies with cyproterone acetate for male contraception.
    Author: Roy S, Chatterjee S.
    Journal: J Steroid Biochem; 1979 Jul; 11(1B):675-80. PubMed ID: 491632.
    Abstract:
    2 studies of the effects of low-dose cyproterone acetate (CA), 1 double-blind (placebo) and 1 using the same subject as case and control, are presented. Daily administration of 10 and 5 mg of CA to 2 groups of normal volunteers over 28 weeks caused a gradual decrease in the count and motility of the sperm, with a concomitant increase in the percentage of nonmotile as well as abnormal and immature sperm. Preovulatory cervical mucus penetration by the ejaculate sperm was markedly inhibited. Levels of acid phosphatase, sialic acid, and glycerylphosphorylcholine in semen decreased progressively, whereas the levels of fructose did not show any significant change. Plasma testosterone levels were decreased in both groups; however, libido and potency were not altered. Liver and kidney functions were also unaffected. After drug therapy was stopped, the changes noted in various parameters gradually reversed toward normal values, although some of the parameters did not reach control levels by the 12-18th weeks posttherapy cessation. In the 2nd study of 3 volunteers who received 10 mg of CA daily for 12-16 weeks, results included a marked decrease in the count, motility, and cervical-mucus-penetrating ability of the sperm. In addition, biochemical constituents of semen were also altered; however, subsequent concurrent administration of 75 mg of mesterolone daily for 6-13 weeks counteracted the CA-induced changes significantly. Use of CA as a male contraceptive is discussed in terms of its possible sites and modes of action.
    [Abstract] [Full Text] [Related] [New Search]